NuCana Faces Nasdaq Compliance Challenge

Nucana ( (NCNA) ) has shared an update.

On June 18, 2025, NuCana plc received a notification from Nasdaq indicating that its American Depositary Shares (ADSs) had fallen below the $1.00 minimum bid price requirement for 30 consecutive trading days. This notice does not immediately affect the listing of NuCana’s ADSs, which continue to trade under the symbol ‘NCNA’. The company has until December 15, 2025, to regain compliance with Nasdaq’s listing requirements, failing which its shares may face delisting. NuCana plans to monitor the situation closely and consider options to meet the compliance requirements.

The most recent analyst rating on (NCNA) stock is a Buy with a $150.00 price target. To see the full list of analyst forecasts on Nucana stock, see the NCNA Stock Forecast page.

Spark’s Take on NCNA Stock

According to Spark, TipRanks’ AI Analyst, NCNA is a Underperform.

Nucana’s overall score is primarily impacted by its financial instability and negative valuation metrics. The significant lack of revenue generation and operational losses are major concerns. Despite showing strong cash management and low leverage, the company’s technical indicators suggest a bearish trend, further weighing down the score. The poor valuation metrics, such as a negative P/E ratio, are offset by potential speculative interest due to the low stock price. The absence of notable earnings call insights or corporate events means these factors did not influence the score.

To see Spark’s full report on NCNA stock, click here.

More about Nucana

NuCana plc operates within the biopharmaceutical industry, focusing on developing innovative therapies for cancer treatment. The company is headquartered in Edinburgh, United Kingdom, and its primary market involves the development and commercialization of novel oncology products.

Average Trading Volume: 138,318,402

Technical Sentiment Signal: Sell

Current Market Cap: $740.2K

Learn more about NCNA stock on TipRanks’ Stock Analysis page.